Novel Allosteric Modulators of G Protein-coupled Receptors*

G protein-coupled receptors (GPCRs) are allosteric proteins, because their signal transduction relies on interactions between topographically distinct, yet conformationally linked, domains. Much of the focus on GPCR allostery in the new millennium, however, has been on modes of targeting GPCR allosteric sites with chemical probes due to the potential for novel therapeutics. It is now apparent that some GPCRs possess more than one targetable allosteric site, in addition to a growing list of putative endogenous modulators. Advances in structural biology are also shedding new insights into mechanisms of allostery, although the complexities of candidate allosteric drugs necessitate rigorous biological characterization.

[1]  K. Gregory,et al.  Discovery of a Novel Chemical Class of mGlu5 Allosteric Ligands with Distinct Modes of Pharmacology , 2010, ACS chemical neuroscience.

[2]  L. Luttrell,et al.  Beyond Desensitization: Physiological Relevance of Arrestin-Dependent Signaling , 2010, Pharmacological Reviews.

[3]  Aron W Fenton,et al.  Allostery: an illustrated definition for the 'second secret of life'. , 2008, Trends in biochemical sciences.

[4]  Arthur Christopoulos,et al.  Signalling bias in new drug discovery: detection, quantification and therapeutic impact , 2012, Nature Reviews Drug Discovery.

[5]  F. Valentin,et al.  Academic drug discovery centres: the economic and organisational sustainability of an emerging model. , 2014, Drug discovery today.

[6]  J. Ellis,et al.  Interactions of alcuronium, TMB-8, and other allosteric ligands with muscarinic acetylcholine receptors: studies with chimeric receptors. , 2000, Molecular pharmacology.

[7]  Arthur Christopoulos,et al.  Endogenous Allosteric Modulators of G Protein–Coupled Receptors , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[8]  J L Benovic,et al.  Agonist-Receptor-Arrestin, an Alternative Ternary Complex with High Agonist Affinity* , 1997, The Journal of Biological Chemistry.

[9]  Jens Meiler,et al.  Structure of a Class C GPCR Metabotropic Glutamate Receptor 1 Bound to an Allosteric Modulator , 2014, Science.

[10]  S. Rasmussen,et al.  Crystal Structure of the β2Adrenergic Receptor-Gs protein complex , 2011, Nature.

[11]  J. Wess,et al.  Activation and allosteric modulation of a muscarinic acetylcholine receptor , 2013, Nature.

[12]  C. Lindsley,et al.  Discovery of molecular switches within the ADX-47273 mGlu5 PAM scaffold that modulate modes of pharmacology to afford potent mGlu5 NAMs, PAMs and partial antagonists. , 2011, Bioorganic & medicinal chemistry letters.

[13]  H. Schiöth,et al.  The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. , 2003, Molecular pharmacology.

[14]  A. Christopoulos,et al.  ALLOSTERIC INTERACTIONS AT MUSCARINIC CHOLINOCEPTORS , 1998, Clinical and experimental pharmacology & physiology.

[15]  M. Bouvier,et al.  Conformational Rearrangements and Signaling Cascades Involved in Ligand-Biased Mitogen-Activated Protein Kinase Signaling through the β1-Adrenergic Receptor , 2008, Molecular Pharmacology.

[16]  P. Sexton,et al.  Synthesis and pharmacological evaluation of analogues of benzyl quinolone carboxylic acid (BQCA) designed to bind irreversibly to an allosteric site of the M ₁ muscarinic acetylcholine receptor. , 2014, Journal of medicinal chemistry.

[17]  J. Changeux,et al.  International Union of Basic and Clinical Pharmacology. XC. Multisite Pharmacology: Recommendations for the Nomenclature of Receptor Allosterism and Allosteric Ligands , 2014, Pharmacological Reviews.

[18]  E. Brown,et al.  L-amino acid sensing by the extracellular Ca2+-sensing receptor. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[19]  T. Kenakin.  New Concepts in Drug Discovery: Collateral Efficacy and Permissive Antagonism , 2005, Nature Reviews Drug Discovery.

[20]  P. Conn,et al.  Allosteric Potentiators of Metabotropic Glutamate Receptor Subtype 5 Have Differential Effects on Different Signaling Pathways in Cortical Astrocytes , 2005, Journal of Pharmacology and Experimental Therapeutics.

[21]  P. Sexton,et al.  Interaction Studies of Multiple Binding Sites on M4 Muscarinic Acetylcholine Receptors , 2006, Molecular Pharmacology.

[22]  N. Birdsall,et al.  Modification of the binding properties of muscarinic receptors by gallamine. , 1983, Molecular pharmacology.

[23]  T. Kenakin,et al.  G Protein-Coupled Receptor Allosterism and Complexing , 2002, Pharmacological Reviews.

[24]  S. Lazareno,et al.  Allosteric interactions of staurosporine and other indolocarbazoles with N-[methyl-(3)H]scopolamine and acetylcholine at muscarinic receptor subtypes: identification of a second allosteric site. , 2000, Molecular pharmacology.

[25]  S. Watson,et al.  A Fully Human, Allosteric Monoclonal Antibody That Activates the Insulin Receptor and Improves Glycemic Control , 2012, Diabetes.

[26]  S. Lazareno,et al.  Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors: radioligand binding studies. , 1998, Molecular pharmacology.

[27]  K. Wreggett,et al.  An Intracellular Allosteric Site for a Specific Class of Antagonists of the CC Chemokine G Protein-Coupled Receptors CCR4 and CCR5 , 2008, Molecular Pharmacology.

[28]  Ali Jazayeri,et al.  Structure of class B GPCR corticotropin-releasing factor receptor 1 , 2013, Nature.

[29]  A. IJzerman,et al.  Amiloride Derivatives and a Nonpeptidic Antagonist Bind at Two Distinct Allosteric Sites in the Human Gonadotropin-Releasing Hormone Receptor , 2008, Molecular Pharmacology.

[30]  Graeme Milligan,et al.  G protein‐coupled receptor hetero‐dimerization: contribution to pharmacology and function , 2009, British journal of pharmacology.

[31]  V. Hilser,et al.  The ensemble nature of allostery , 2014, Nature.

[32]  P Jeffrey Conn,et al.  Discovery of Novel Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Reveals Chemical and Functional Diversity and In Vivo Activity in Rat Behavioral Models of Anxiolytic and Antipsychotic Activity , 2010, Molecular Pharmacology.

[33]  M. Hollenberg,et al.  Proteinase‐activated receptor‐4: evaluation of tethered ligand‐derived peptides as probes for receptor function and as inflammatory agonists in vivo , 2004, British journal of pharmacology.

[34]  U. Holzgrabe,et al.  Rational design of dualsteric GPCR ligands: quests and promise , 2010, British journal of pharmacology.

[35]  Jens Meiler,et al.  Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders , 2014, Nature Reviews Drug Discovery.

[36]  A. Conigrave,et al.  A Double Mutation in the Extracellular Ca2+-sensing Receptor's Venus Flytrap Domain That Selectively Disables l-Amino Acid Sensing* , 2005, Journal of Biological Chemistry.

[37]  Ryan T. Strachan,et al.  Allosteric Modulation of β-Arrestin-biased Angiotensin II Type 1 Receptor Signaling by Membrane Stretch* , 2014, The Journal of Biological Chemistry.

[38]  J. Pin,et al.  A virtual screening hit reveals new possibilities for developing group III metabotropic glutamate receptor agonists. , 2010, Journal of medicinal chemistry.

[39]  Benjamin G Tehan,et al.  Structure of Class B GPCRs: new horizons for drug discovery , 2014, British journal of pharmacology.

[40]  J. Pin,et al.  Interaction of Novel Positive Allosteric Modulators of Metabotropic Glutamate Receptor 5 with the Negative Allosteric Antagonist Site Is Required for Potentiation of Receptor Responses , 2007, Molecular Pharmacology.

[41]  J. Pin,et al.  A critical pocket close to the glutamate binding site of mGlu receptors opens new possibilities for agonist design , 2011, Neuropharmacology.

[42]  M. Caron,et al.  Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. , 1999, Science.

[43]  T. Huber,et al.  Chemical biology methods for investigating G protein-coupled receptor signaling. , 2014, Chemistry and Biology.

[44]  Jacques Monod,et al.  Allosteric Proteins and Cellular Control Systems , 1989 .

[45]  M. Rask-Andersen,et al.  Trends in the exploitation of novel drug targets , 2011, Nature Reviews Drug Discovery.

[46]  Laurence J. Miller,et al.  Seven Transmembrane Receptors as Shapeshifting Proteins: The Impact of Allosteric Modulation and Functional Selectivity on New Drug Discovery , 2010, Pharmacological Reviews.

[47]  C. Lindsley,et al.  Challenges in the development of mGluR5 positive allosteric modulators: the discovery of CPPHA. , 2007, Bioorganic & medicinal chemistry letters.

[48]  Arthur Christopoulos,et al.  Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders , 2009, Nature Reviews Drug Discovery.

[49]  A. Doré,et al.  Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain , 2014, Nature.

[50]  N. Kaneider,et al.  Reversing systemic inflammatory response syndrome with chemokine receptor pepducins , 2005, Nature Medicine.

[51]  E. Novellino,et al.  Pharmacological folding chaperones act as allosteric ligands of Frizzled4. , 2015, Nature chemical biology.

[52]  Joanne Baltos,et al.  Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist , 2014, Proceedings of the National Academy of Sciences.

[53]  I. Goldfine,et al.  Detailed Mechanistic Analysis of Gevokizumab, an Allosteric Anti–IL-1β Antibody with Differential Receptor-Modulating Properties , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[54]  Arthur Christopoulos,et al.  Emerging paradigms in GPCR allostery: implications for drug discovery , 2013, Nature Reviews Drug Discovery.

[55]  Kurt Wüthrich,et al.  Biased Signaling Pathways in β2-Adrenergic Receptor Characterized by 19F-NMR , 2012, Science.

[56]  P. Larsen,et al.  Kinetic Approach to Pathway Attenuation Using XOMA 052, a Regulatory Therapeutic Antibody That Modulates Interleukin-1β Activity , 2010, The Journal of Biological Chemistry.

[57]  D. Koshland,et al.  Comparison of experimental binding data and theoretical models in proteins containing subunits. , 1966, Biochemistry.

[58]  P Jeffrey Conn,et al.  Molecular Insights into Metabotropic Glutamate Receptor Allosteric Modulation , 2015, Molecular Pharmacology.

[59]  Albert C. Pan,et al.  Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs , 2013, Nature.

[60]  S. Lazareno,et al.  Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity. , 2004, Molecular pharmacology.

[61]  John P. Overington,et al.  How many drug targets are there? , 2006, Nature Reviews Drug Discovery.

[62]  A. Christopoulos.  Allosteric binding sites on cell-surface receptors: novel targets for drug discovery , 2002, Nature Reviews Drug Discovery.

[63]  Kaixian Chen,et al.  A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice , 2007, Proceedings of the National Academy of Sciences.

[64]  K. Wüthrich,et al.  Fluorine-19 NMR of integral membrane proteins illustrated with studies of GPCRs. , 2013, Current opinion in structural biology.

[65]  XMetA, an allosteric monoclonal antibody to the insulin receptor, improves glycaemic control in mice with diet‐induced obesity , 2013, Diabetes, obesity & metabolism.

[66]  John R. James,et al.  BRET analysis of GPCR oligomerization: newer does not mean better , 2007, Nature Methods.

[67]  T. Arakawa,et al.  Reversibly bound chloride in the atrial natriuretic peptide receptor hormone‐binding domain: Possible allosteric regulation and a conserved structural motif for the chloride‐binding site , 2010, Protein science : a publication of the Protein Society.

[68]  M. Mammen,et al.  A Novel Multivalent Ligand That Bridges the Allosteric and Orthosteric Binding Sites of the M2 Muscarinic Receptor , 2007, Molecular Pharmacology.

[69]  P. Sexton,et al.  The best of both worlds? Bitopic orthosteric/allosteric ligands of g protein-coupled receptors. , 2012, Annual review of pharmacology and toxicology.

[70]  S. Lazareno,et al.  Analogs of WIN 62,577 define a second allosteric site on muscarinic receptors. , 2002, Molecular pharmacology.

[71]  S. Charlton,et al.  A common intracellular allosteric binding site for antagonists of the CXCR2 receptor , 2010, British journal of pharmacology.

[72]  H. Lavreysen,et al.  Functional Impact of Allosteric Agonist Activity of Selective Positive Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 in Regulating Central Nervous System Function , 2012, Molecular Pharmacology.

[73]  E. Brown,et al.  Three Adjacent Serines in the Extracellular Domains of the CaR Are Required for l-Amino Acid-mediated Potentiation of Receptor Function* , 2002, The Journal of Biological Chemistry.

[74]  K. Gregory,et al.  A Novel Metabotropic Glutamate Receptor 5 Positive Allosteric Modulator Acts at a Unique Site and Confers Stimulus Bias to mGlu5 Signaling , 2013, Molecular Pharmacology.

[75]  Hualiang Jiang,et al.  Structure of the CCR5 Chemokine Receptor–HIV Entry Inhibitor Maraviroc Complex , 2013, Science.

[76]  Jens Meiler,et al.  Allosteric modulation of metabotropic glutamate receptors: Structural insights and therapeutic potential , 2011, Neuropharmacology.

[77]  P. Sexton,et al.  Allostery in GPCRs: 'MWC' revisited. , 2011, Trends in biochemical sciences.

[78]  K. Gregory,et al.  Allosteric Modulation of Muscarinic Acetylcholine Receptors , 2007, Current neuropharmacology.

[79]  A. Christopoulos,et al.  Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia , 2008, Proceedings of the National Academy of Sciences.

[80]  Vadim Cherezov,et al.  Structural basis for Smoothened receptor modulation and chemoresistance to anticancer drugs , 2014, Nature Communications.

[81]  P. Sexton,et al.  Molecular Mechanisms of Action and In Vivo Validation of an M4 Muscarinic Acetylcholine Receptor Allosteric Modulator with Potential Antipsychotic Properties , 2010, Neuropsychopharmacology.

[82]  Robert J. Lefkowitz,et al.  Transduction of Receptor Signals by ß-Arrestins , 2005, Science.

[83]  P. Jeffrey Conn,et al.  N-{4-Chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA) Acts through a Novel Site as a Positive Allosteric Modulator of Group 1 Metabotropic Glutamate Receptors , 2008, Molecular Pharmacology.

[84]  J. Proska,et al.  Mechanisms of steric and cooperative actions of alcuronium on cardiac muscarinic acetylcholine receptors. , 1994, Molecular pharmacology.

[85]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2000, Science.

[86]  P Jeffrey Conn,et al.  A Novel Selective Allosteric Modulator Potentiates the Activity of Native Metabotropic Glutamate Receptor Subtype 5 in Rat Forebrain , 2004, Journal of Pharmacology and Experimental Therapeutics.

[87]  K. Nicolaou.  Advancing the drug discovery and development process. , 2014, Angewandte Chemie.

[88]  P. Sexton,et al.  Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. , 2007, Trends in pharmacological sciences.

[89]  P. Sexton,et al.  Differential Activation and Modulation of the Glucagon-Like Peptide-1 Receptor by Small Molecule Ligands , 2013, Molecular Pharmacology.

[90]  A. Mathiowetz,et al.  A potentiator of orthosteric ligand activity at GLP-1R acts via covalent modification. , 2014, Nature chemical biology.

[91]  R. Lefkowitz,et al.  Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors. , 2012, Annual review of pharmacology and toxicology.

[92]  O. Wassermann,et al.  Inhibition of the actions of carbachol and DFP on guinea pig isolated atria by alkane-bis-ammonium compounds. , 1969, European journal of pharmacology.

[93]  P Jeffrey Conn,et al.  "Molecular switches" on mGluR allosteric ligands that modulate modes of pharmacology. , 2011, Biochemistry.

[94]  P. Gorostiza,et al.  An allosteric modulator to control endogenous G protein-coupled receptors with light. , 2014, Nature chemical biology.

[95]  Arthur Christopoulos,et al.  A Novel Mechanism of G Protein-coupled Receptor Functional Selectivity , 2008, Journal of Biological Chemistry.

[96]  J. Changeux,et al.  ON THE NATURE OF ALLOSTERIC TRANSITIONS: A PLAUSIBLE MODEL. , 1965, Journal of molecular biology.

[97]  H. Hamm,et al.  Structural basis of function in heterotrimeric G proteins , 2006, Quarterly Reviews of Biophysics.

[98]  D. Nicholls,et al.  Identification of a Putative Intracellular Allosteric Antagonist Binding-Site in the CXC Chemokine Receptors 1 and 2 , 2008, Molecular Pharmacology.

[99]  F. Mitchelson,et al.  THE INHIBITORY EFFECT OF GALLAMINE ON MUSCARINIC RECEPTORS , 1976, British journal of pharmacology.